Indometacin farnesil
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | None |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | To indometacin |
Biological half-life | 1.5 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | 85801-02-1 |
PubChem (CID) | 5282183 |
ChemSpider | 4445378 |
Chemical and physical data | |
Formula | C34H40ClNO4 |
Molar mass | 562.14 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.
External links
This article is issued from Wikipedia - version of the 4/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.